Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

[1]  P. Queirolo,et al.  Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Schadendorf,et al.  Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Schadendorf,et al.  Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin , 2002 .

[4]  J. Lee,et al.  Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  O. Nanni,et al.  Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Bröcker,et al.  Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM) , 2002, British Journal of Cancer.

[7]  A. Hauschild,et al.  Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) , 2001, British Journal of Cancer.

[8]  R. Mcgarry,et al.  Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials , 2001, Melanoma research.

[9]  R. Dummer,et al.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D P Byar,et al.  A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. , 1984, Biometrics.